Sanofi's Sale of Doliprane to US Fund Sparks Sovereignty Concerns

French lawmakers urge government intervention as Sanofi plans to sell its Opella unit, producer of Doliprane, to American investment firm CD&R.

Sanofi announced the sale of its Opella unit, responsible for Doliprane production, to the American investment fund CD&R, raising concerns about France's pharmaceutical sovereignty.
French MP Charles Rodwell, alongside 62 other deputies, has appealed to the Ministry of Economy to scrutinize and potentially block the sale, citing national security and economic concerns.
The sale could lead to changes in Doliprane pricing and availability, with potential risks of shortages due to reduced prioritization of the French market.
Currently, Doliprane's active ingredient, paracetamol, is manufactured outside France, highlighting challenges in achieving pharmaceutical self-sufficiency.
The French government is urged to use foreign investment control measures to protect strategic health sectors, aligning with its France 2030 investment plan.